A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma

Inclusion Criteria: * Histologically or cytologically confirmed Stage III (unresectable) or Stage IV melanoma * No prior systemic treatment or Cytotoxic chemotherapy for advanced melanoma (Stage III or Stage IV) * If the subject is female, she must be non-pregnant and non-lactating at the Baseline Visit. All sexually active males and females of childbearing potential must agree to use an adequate method of contraception throughout the study period * Eastern Cooperative Oncology Group (ECOG) performance status \</= 1 * Life expectancy \> 12 weeks * At least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors ({RECIST} version 1.1) * Subjects with a previous history of non-melanoma malignancy must have undergone curative therapy for all prior malignancies and be considered disease free for at least 5 years Exclusion Criteria: * Major surgery within 21 days of the Baseline Visit * Presence or history of brain metastases * Primary ocular, choroidal or mucosal melanoma * Known history of positive test for Hepatitis B surface Antigen (HsbAg) or Hepatitis C antibody or history of positive test for Human Immunodeficiency Virus (HIV) * Hypersensitivity to docetaxel or polysorbate 80 * Neuropathy greater than or equal to Grade 2 at Baseline Visit * The subject has been previously treated with YM155 * Inadequate marrow, hepatic, and/or renal functions